Prostate Cancer | Fred Saad, MD

published 5 months ago by Dr Neil Love

Prostate Cancer Update, Issue 1, 2021 — Part 1: Our interview with Dr Saad highlights the following topics as well as cases from his practice: Optimal integration of secondary hormonal therapy into the management of nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer — Presentation (0:00) Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (21:42) Perspective on the benefits of early initiation of secondary hormonal therapy for patients with prostate cancer (29:20) Role of immunotherapy for prostate cancer; optimal timing for the initiation of androgen deprivation therapy (ADT) for patients with M0 disease (33:34) Phase III HERO study comparing relugolix to leuprolide for advanced prostate cancer (39:37) Prevention and management of side effects associated with ADT (45:39) Impact of PSA doubling time on eligibility and outcomes of patients with nonmetastatic castration-resistant prostate cancer (CRPC) who received enzalutamide, apalutamide and darolutamide in the Phase III PROSPER, SPARTAN and ARAMIS trials, respectively (49:50) Efficacy and tolerability of enzalutamide, apalutamide and darolutamide in the PROSPER, SPARTAN and ARAMIS trials for patients with nonmetastatic CRPC (53:56) Benefits and risks with enzalutamide, apalutamide and darolutamide (58:52) Outcomes with the addition of docetaxel versus abiraterone to ADT for metastatic hormone sensitive prostate cancer; impact of disease burden on therapeutic decision-making (1:05:02) Novel agents and approaches under investigation for patients with prostate cancer (1:12:49) CME information and select publications

more episodes from Research To Practice | Oncology Videos